Erik J.M. van Bommel

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar et al. · Kidney International · 2019 · 331 citations · Full text

Metabolic Syndrome, Diabetes Management, Renal Function +13

Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes

Erik J.M. van Bommel, Hilde Herrema, Mark Davids et al. · Diabetes & Metabolism · 2019 · 80 citations

Diabetes Management, Dysbiosis, Diabetes +8

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Erik J.M. van Bommel, Mark M. Smits, Danique Ruiter et al. · Journal of Hypertension · 2020 · 30 citations · Full text

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes

Erik J.M. van Bommel, Frank Geurts, Marcel H.A. Muskiet et al. · Clinical Science · 2020 · 30 citations · Full text

The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial

Erik J.M. van Bommel, Renate T. de Jongh, Annemieke C. Heijboer et al. · Bone · 2018 · 21 citations

Obesity, Metabolic Syndrome, Bone Disease +13